{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:35:06Z","timestamp":1785407706495,"version":"3.56.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000858","name":"University of Sheffield","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005362","name":"Universita degli Studi di Bari Aldo Moro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.bone.2021.115907","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T16:18:22Z","timestamp":1615133902000},"page":"115907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["\u201cThe use of bisphosphonates to treat skeletal complications in solid tumours\u201d"],"prefix":"10.1016","volume":"147","author":[{"given":"S.","family":"D'Oronzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bone.2021.115907_bb0005","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4103\/1008-682X.126378","article-title":"Treatment sequencing in metastatic castrate-resistant prostate cancer","volume":"16","author":"Sartor","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1016\/j.bone.2021.115907_bb0010","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399408000616","article-title":"Molecular mechanisms and treatment of bone metastasis","volume":"10","author":"Clines","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"issue":"10","key":"10.1016\/j.bone.2021.115907_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102587","article-title":"Prostate cancer and bone metastases: the underlying mechanisms","volume":"20","author":"Wong","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bone.2021.115907_bb0020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.critrevonc.2019.04.020","article-title":"The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone","volume":"139","author":"Hussain","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bone.2021.115907_bb0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canep.2019.05.013","article-title":"Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: a 12-year longitudinal nationwide healthcare database study","volume":"61","author":"Baek","year":"2019","journal-title":"Cancer Epidemiol."},{"issue":"4","key":"10.1016\/j.bone.2021.115907_bb0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jbo.2013.09.001","article-title":"Incidence, consequences and treatment of bone metastases in breast cancer patients-experience from a single cancer Centre","volume":"2","author":"Kuchuk","year":"2013","journal-title":"J Bone Oncol"},{"issue":"9","key":"10.1016\/j.bone.2021.115907_bb0035","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/cncr.30505","article-title":"Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer","volume":"123","author":"Klaassen","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bone.2021.115907_bb0040","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s13277-015-3907-z","article-title":"Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases","volume":"37","author":"Ulas","year":"2016","journal-title":"Tumour Biol."},{"issue":"6","key":"10.1016\/j.bone.2021.115907_bb0045","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1634\/theoncologist.5-6-463","article-title":"Management of bone metastases","volume":"5","author":"Coleman","year":"2000","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.bone.2021.115907_bb0050","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.critrevonc.2005.03.011","article-title":"Management of bone metastases in cancer: a review","volume":"56","author":"Selvaggi","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.bone.2021.115907_bb0055","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.21873\/anticanres.12817","article-title":"Metastatic spinal cord compression: unraveling the diagnostic and therapeutic challenges","volume":"38","author":"Boussios","year":"2018","journal-title":"Anticancer Res."},{"issue":"14","key":"10.1016\/j.bone.2021.115907_bb0060","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1516539","article-title":"Acute spinal cord compression","volume":"376","author":"Ropper","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1\u20133","key":"10.1016\/j.bone.2021.115907_bb0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000181252","article-title":"Humoral hypercalcemia of malignancy","volume":"32","author":"Martin","year":"1989","journal-title":"Horm. Res."},{"issue":"8 Suppl","key":"10.1016\/j.bone.2021.115907_bb0070","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2021.115907_bb0075","doi-asserted-by":"crossref","first-page":"w14440","DOI":"10.4414\/smw.2017.14440","article-title":"Bone targeted therapies in advanced breast cancer","volume":"147","author":"Biskup","year":"2017","journal-title":"Swiss Med. Wkly."},{"issue":"1","key":"10.1016\/j.bone.2021.115907_bb0080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/pcan.2016.62","article-title":"Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials","volume":"20","author":"Saad","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.bone.2021.115907_bb0085","first-page":"49","article-title":"Quality of life measurement in bone metastases: a literature review","volume":"1","author":"Tharmalingam","year":"2008","journal-title":"J. Pain Res."},{"issue":"5","key":"10.1016\/j.bone.2021.115907_bb0090","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/erp.09.50","article-title":"Understanding the EORTC QLQ-BM22, the module for patients with bone metastases","volume":"9","author":"Chow","year":"2009","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.bone.2021.115907_bb0095","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.7314\/APJCP.2016.17.3.1405","article-title":"Assessing the EORTC QLQ-BM22 module using Rasch modeling and confirmatory factor analysis across countries: a comprehensive psychometric evaluation in patients with bone metastases","volume":"17","author":"Lin","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.bone.2021.115907_bb0100","doi-asserted-by":"crossref","unstructured":"R.E. Coleman, Clinical features of metastatic bone disease and risk of skeletal morbidity, Clin Cancer Res 12(20 Pt 2) (2006) 6243s\u20136249s.","DOI":"10.1158\/1078-0432.CCR-06-0931"},{"key":"10.1016\/j.bone.2021.115907_bb0105","doi-asserted-by":"crossref","unstructured":"M.H. Wong, M.R. Stockler, N. Pavlakis, Bisphosphonates and other bone agents for breast cancer, Cochrane Database Syst Rev (2) (2012) CD003474.","DOI":"10.1002\/14651858.CD003474.pub3"},{"issue":"1","key":"10.1016\/j.bone.2021.115907_bb0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2011.02.003","article-title":"Bisphosphonates in oncology","volume":"49","author":"Coleman","year":"2011","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2021.115907_bb0115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"23","key":"10.1016\/j.bone.2021.115907_bb0120","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2021.115907_bb0125","doi-asserted-by":"crossref","first-page":"115570","DOI":"10.1016\/j.bone.2020.115570","article-title":"Bisphosphonates and breast cancer - from cautious palliation to saving lives","volume":"140","author":"Coleman","year":"2020","journal-title":"Bone"},{"issue":"8566","key":"10.1016\/j.bone.2021.115907_bb0130","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(87)92555-4","article-title":"Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment","volume":"2","author":"van Holten-Verzantvoort","year":"1987","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bone.2021.115907_bb0135","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/bjc.1988.272","article-title":"Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)","volume":"58","author":"Coleman","year":"1988","journal-title":"Br. J. Cancer"},{"issue":"27","key":"10.1016\/j.bone.2021.115907_bb0140","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/138161210793563635","article-title":"Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages","volume":"16","author":"Roelofs","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bone.2021.115907_bb0145","doi-asserted-by":"crossref","first-page":"115493","DOI":"10.1016\/j.bone.2020.115493","article-title":"Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton","volume":"139","author":"Rogers","year":"2020","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2021.115907_bb0150","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/bcp.13867","article-title":"Pharmacology of bisphosphonates","volume":"85","author":"Cremers","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bone.2021.115907_bb0155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00223-017-0353-5","article-title":"Bone-targeted therapies in cancer-induced bone disease","volume":"102","author":"Sousa","year":"2018","journal-title":"Calcif. Tissue Int."},{"issue":"11","key":"10.1016\/j.bone.2021.115907_bb0160","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00262-010-0887-0","article-title":"Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients","volume":"59","author":"Cabillic","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.bone.2021.115907_bb0165","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s00018-013-1495-x","article-title":"Neutrophil uptake of nitrogen-bisphosphonates leads to the suppression of human peripheral blood gammadelta T cells","volume":"71","author":"Kalyan","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.bone.2021.115907_bb0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/2159-8290.CD-14-0621","article-title":"Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer","volume":"5","author":"Junankar","year":"2015","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.bone.2021.115907_bb0175","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.bbagen.2012.07.013","article-title":"Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid","volume":"1820","author":"Dedes","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bone.2021.115907_bb0180","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/bonekey.2013.1","article-title":"Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities","volume":"2","author":"Clezardin","year":"2013","journal-title":"Bonekey Rep"},{"issue":"10","key":"10.1016\/j.bone.2021.115907_bb0185","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3727\/096504010X12671222663638","article-title":"Zoledronate stimulates gamma delta T cells in prostate cancer patients","volume":"18","author":"Naoe","year":"2010","journal-title":"Oncol. Res."},{"issue":"1","key":"10.1016\/j.bone.2021.115907_bb0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.bone.2021.115907_bb0195","first-page":"1551","article-title":"Cancer-induced hypercalcemia","volume":"29","author":"Lumachi","year":"2009","journal-title":"Anticancer Res."},{"issue":"2 Suppl 5","key":"10.1016\/j.bone.2021.115907_bb0200","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0093-7754(03)00170-2","article-title":"The effects of gallium nitrate on bone resorption","volume":"30","author":"Bockman","year":"2003","journal-title":"Semin. Oncol."},{"issue":"7","key":"10.1016\/j.bone.2021.115907_bb0205","doi-asserted-by":"crossref","first-page":"327","DOI":"10.12968\/ijpn.2013.19.7.327","article-title":"The management of hypercalcaemia in advanced cancer","volume":"19","author":"Pettifer","year":"2013","journal-title":"Int. J. Palliat. Nurs."},{"issue":"5","key":"10.1016\/j.bone.2021.115907_bb0210","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/bjc.1995.502","article-title":"A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy","volume":"72","author":"Purohit","year":"1995","journal-title":"Br. J. Cancer"},{"issue":"2 Suppl 6","key":"10.1016\/j.bone.2021.115907_bb0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0093-7754(01)90261-1","article-title":"Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program","volume":"28","author":"Major","year":"2001","journal-title":"Semin. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2021.115907_bb0220","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bone.2021.115907_bb0225","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2021.115907_bb0230","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11914-017-0354-3","article-title":"Bone pain and muscle weakness in cancer patients","volume":"15","author":"Milgrom","year":"2017","journal-title":"Curr Osteoporos Rep"},{"issue":"9","key":"10.1016\/j.bone.2021.115907_bb0235","article-title":"Pain management in metastatic bone disease: a literature review","volume":"10","author":"Ahmad","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.bone.2021.115907_bb0240","doi-asserted-by":"crossref","unstructured":"G. Early Breast Cancer Trialists' Collaborative, Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials, Lancet 386(10001) (2015) 1353\u20131361.","DOI":"10.1016\/S0140-6736(15)60908-4"},{"issue":"2","key":"10.1016\/j.bone.2021.115907_bb0245","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bjc.1988.194","article-title":"Biochemical prediction of response of bone metastases to treatment","volume":"58","author":"Coleman","year":"1988","journal-title":"Br. J. Cancer"},{"issue":"8 Pt 1","key":"10.1016\/j.bone.2021.115907_bb0250","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/clinchem\/45.8.1240","article-title":"Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases","volume":"45","author":"Berruti","year":"1999","journal-title":"Clin. Chem."},{"issue":"22","key":"10.1016\/j.bone.2021.115907_bb0255","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2021.115907_bb0260","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.urology.2007.03.071","article-title":"Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer","volume":"70","author":"Smith","year":"2007","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.bone.2021.115907_bb0265","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bone.2021.115907_bb0270","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.clon.2012.11.004","article-title":"Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses","volume":"25","author":"Lipton","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"8","key":"10.1016\/j.bone.2021.115907_bb0275","first-page":"871","article-title":"Associations between serum bone biomarkers in early breast cancer and development of bone metastasis: results from the AZURE (BIG01\/04) trial","volume":"110","author":"Brown","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bone.2021.115907_bb0280","series-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences, Drugs","author":"Braal","year":"2020"},{"key":"10.1016\/j.bone.2021.115907_bb0285","doi-asserted-by":"crossref","unstructured":"F. Cardoso, S. Paluch-Shimon, E. Senkus, G. Curigliano, M.S. Aapro, F. Andr\u00e9, C.H. Barrios, J. Bergh, G.S. Bhattacharyya, L. Biganzoli, F. Boyle, M.J. Cardoso, L.A. Carey, J. Cort\u00e9s, N.S. El Saghir, M. Elzayat, A. Eniu, L. Fallowfield, P.A. Francis, K. Gelmon, J. Gligorov, R. Haidinger, N. Harbeck, X. Hu, B. Kaufman, R. Kaur, B.E. Kiely, S.-B. Kim, N.U. Lin, S.A. Mertz, S. Neciosup, B.V. Offersen, S. Ohno, O. Pagani, A. Prat, F. Penault-Llorca, H.S. Rugo, G.W. Sledge, C. Thomssen, D.A. Vorobiof, T. Wiseman, B. Xu, L. Norton, A. Costa, E.P. Winer, 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5), Annals of Oncology 31 (9) 1623\u20131649.","DOI":"10.1016\/j.annonc.2020.09.010"},{"key":"10.1016\/j.bone.2021.115907_bb0290","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O\u2019Carrigan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.bone.2021.115907_bb0295","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bone.2021.115907_bb0300","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bone.2021.115907_bb0305","doi-asserted-by":"crossref","unstructured":"N. Pavlakis, R. Schmidt, M. Stockler, Bisphosphonates for breast cancer, Cochrane Database Syst Rev (3) (2005) CD003474.","DOI":"10.1002\/14651858.CD003474.pub2"},{"key":"10.1016\/j.bone.2021.115907_bb0310","doi-asserted-by":"crossref","first-page":"115715","DOI":"10.1016\/j.bone.2020.115715","article-title":"Clodronate","volume":"143","author":"McCloskey","year":"2021","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2021.115907_bb0315","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.bone.2021.115907_bb0320","doi-asserted-by":"crossref","unstructured":"G.N. Hortobagyi, R.L. Theriault, L. Porter, D. Blayney, A. Lipton, C. Sinoff, H. Wheeler, J.F. Simeone, J. Seaman, R.D. Knight, Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group, N Engl J Med 335(24) (1996) 1785\u201391.","DOI":"10.1056\/NEJM199612123352401"},{"key":"10.1016\/j.bone.2021.115907_bb0325","doi-asserted-by":"crossref","unstructured":"R.L. Theriault, A. Lipton, G.N. Hortobagyi, R. Leff, S. Gluck, J.F. Stewart, S. Costello, I. Kennedy, J. Simeone, J.J. Seaman, R.D. Knight, K. Mellars, M. Heffernan, D.J. Reitsma, Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group, J Clin Oncol 17(3) (1999) 846\u201354.","DOI":"10.1200\/JCO.1999.17.3.846"},{"issue":"9","key":"10.1016\/j.bone.2021.115907_bb0330","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2021.115907_bb0335","doi-asserted-by":"crossref","unstructured":"G.N. Hortobagyi, R.L. Theriault, A. Lipton, L. Porter, D. Blayney, C. Sinoff, H. Wheeler, J.F. Simeone, J.J. Seaman, R.D. Knight, M. Heffernan, K. Mellars, D.J. Reitsma, Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group, J Clin Oncol 16(6) (1998) 2038\u201344.","DOI":"10.1200\/JCO.1998.16.6.2038"},{"issue":"4C","key":"10.1016\/j.bone.2021.115907_bb0340","first-page":"3383","article-title":"Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study","volume":"19","author":"Hultborn","year":"1999","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.bone.2021.115907_bb0345","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2021.115907_bb0350","doi-asserted-by":"crossref","unstructured":"P. Ottewell, C. Wilson, Bone-targeted agents in breast cancer: do we now have all the answers?, Breast Cancer (Auckl.) 13 (2019) 1178223419843501.","DOI":"10.1177\/1178223419843501"},{"issue":"8","key":"10.1016\/j.bone.2021.115907_bb0355","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bone.2021.115907_bb0360","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Barrett-Lee","year":"2014","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.bone.2021.115907_bb0365","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.bone.2021.115907_bb0370","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1158\/1078-0432.CCR-13-2275","article-title":"Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis","volume":"19","author":"Palmieri","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bone.2021.115907_bb0375","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40487-020-00119-z","article-title":"Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting","volume":"8","author":"Ng","year":"2020","journal-title":"Oncol Ther"},{"key":"10.1016\/j.bone.2021.115907_bb0380","doi-asserted-by":"crossref","unstructured":"N.W. Clarke, A. Ali, F.C. Ingleby, A. Hoyle, C.L. Amos, G. Attard, C.D. Brawley, J. Calvert, S. Chowdhury, A. Cook, W. Cross, D.P. Dearnaley, H. Douis, D. Gilbert, S. Gillessen, R.J. Jones, R.E. Langley, A. MacNair, Z. Malik, M.D. Mason, D. Matheson, R. Millman, C.C. Parker, A.W.S. Ritchie, H. Rush, J.M. Russell, J. Brown, S. Beesley, A. Birtle, L. Capaldi, J. Gale, S. Gibbs, A. Lydon, A. Nikapota, A. Omlin, J.M. O'Sullivan, O. Parikh, A. Protheroe, S. Rudman, N.N. Srihari, M. Simms, J.S. Tanguay, S. Tolan, J. Wagstaff, J. Wallace, J. Wylie, A. Zarkar, M.R. Sydes, M.K.B. Parmar, N.D. James, Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial, Ann Oncol 30(12) (2019) 1992\u20132003.","DOI":"10.1093\/annonc\/mdz396"},{"key":"10.1016\/j.bone.2021.115907_bb0385","unstructured":"ESMO."},{"issue":"17","key":"10.1016\/j.bone.2021.115907_bb0390","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"17","key":"10.1016\/j.bone.2021.115907_bb0395","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"Ernst","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.bone.2021.115907_bb0400","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2021.115907_bb0405","doi-asserted-by":"crossref","unstructured":"F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J.L. Chin, J.J. Vinholes, J.A. Goas, B. Chen, G. Zoledronic Acid Prostate Cancer Study, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst 94(19) (2002) 1458\u201368.","DOI":"10.1093\/jnci\/94.19.1458"},{"key":"10.1016\/j.bone.2021.115907_bb0410","doi-asserted-by":"crossref","unstructured":"N. James, S. Pirrie, A. Pope, D. Barton, L. Andronis, I. Goranitis, S. Collins, D. McLaren, J. O'Sullivan, C. Parker, E. Porfiri, J. Staffurth, A. Stanley, J. Wylie, S. Beesley, A. Birtle, J. Brown, P. Chakraborti, M. Russell, L. Billingham, TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer, Health Technol Assess 20(53) (2016) 1\u2013288.","DOI":"10.3310\/hta20530"},{"key":"10.1016\/j.bone.2021.115907_bb0415","doi-asserted-by":"crossref","unstructured":"N.D. James, M.R. Sydes, N.W. Clarke, M.D. Mason, D.P. Dearnaley, M.R. Spears, A.W. Ritchie, C.C. Parker, J.M. Russell, G. Attard, J. de Bono, W. Cross, R.J. Jones, G. Thalmann, C. Amos, D. Matheson, R. Millman, M. Alzouebi, S. Beesley, A.J. Birtle, S. Brock, R. Cathomas, P. Chakraborti, S. Chowdhury, A. Cook, T. Elliott, J. Gale, S. Gibbs, J.D. Graham, J. Hetherington, R. Hughes, R. Laing, F. McKinna, D.B. McLaren, J.M. O'Sullivan, O. Parikh, C. Peedell, A. Protheroe, A.J. Robinson, N. Srihari, R. Srinivasan, J. Staffurth, S. Sundar, S. Tolan, D. Tsang, J. Wagstaff, M.K. Parmar, S. investigators, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet 387(10024) (2016) 1163\u201377.","DOI":"10.1016\/S0140-6736(15)01037-5"},{"issue":"11","key":"10.1016\/j.bone.2021.115907_bb0420","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2021.115907_bb0425","doi-asserted-by":"crossref","unstructured":"A. Tombal. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.5007.","DOI":"10.1200\/JCO.2019.37.15_suppl.5007"},{"issue":"12","key":"10.1016\/j.bone.2021.115907_bb0430","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bone.2021.115907_bb0435","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","article-title":"Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity","volume":"3","author":"Hirsh","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.bone.2021.115907_bb0440","first-page":"5245","article-title":"Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis","volume":"29","author":"Spizzo","year":"2009","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.bone.2021.115907_bb0445","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10147-010-0179-x","article-title":"Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer","volume":"16","author":"Francini","year":"2011","journal-title":"Int. J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bone.2021.115907_bb0450","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.3892\/or.2016.4741","article-title":"Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations","volume":"35","author":"Feng","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bone.2021.115907_bb0455","doi-asserted-by":"crossref","unstructured":"A. Lipton, A. Colombo-Berra, R.M. Bukowski, L. Rosen, M. Zheng, G. Urbanowitz, Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid, Clin. Cancer Res. 10(18 Pt 2) (2004) 6397S-403S.","DOI":"10.1158\/1078-0432.CCR-040030"},{"issue":"6","key":"10.1016\/j.bone.2021.115907_bb0460","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s10147-018-1310-7","article-title":"Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis","volume":"23","author":"Hosaka","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bone.2021.115907_bb0465","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clgc.2014.07.002","article-title":"Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial","volume":"13","author":"Broom","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.bone.2021.115907_bb0470","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JOP.2011.000212","article-title":"American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer","volume":"7","author":"Van Poznak","year":"2011","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.bone.2021.115907_bb0475","doi-asserted-by":"crossref","unstructured":"R. Coleman, J.J. Body, M. Aapro, P. Hadji, J. Herrstedt, E.G.W. Group, Bone health in cancer patients: ESMO clinical practice guidelines, Ann Oncol 25 Suppl 3 (2014) iii124\u201337.","DOI":"10.1093\/annonc\/mdu103"},{"issue":"7","key":"10.1016\/j.bone.2021.115907_bb0480","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.bone.2021.115907_bb0485","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bone.2021.115907_bb0490","doi-asserted-by":"crossref","unstructured":"W.J. Coleman R.E., Houston S., Agrawal R., Purohit O., Hayward L., Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer., Journal of Clinical Oncology. (2012).","DOI":"10.1200\/jco.2012.30.15_suppl.511"},{"key":"10.1016\/j.bone.2021.115907_bb0495","author":"ESMO"},{"key":"10.1016\/j.bone.2021.115907_bb0500","doi-asserted-by":"crossref","unstructured":"M. Clemons, M. Ong, C. Stober, S. Ernst, C. Booth, C. Canil, M. Mates, A. Robinson, P. Blanchette, A.A. Joy, J. Hilton, O. Aseyev, G. Pond, A. Jeong, B. Hutton, S. Mazzarello, L. Vandermeer, I. Kushnir, D. Fergusson, R.E. investigators, A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer, Eur J Cancer 142 (2021) 132\u2013140.","DOI":"10.1016\/j.ejca.2020.08.019"},{"issue":"3","key":"10.1016\/j.bone.2021.115907_bb0505","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10549-019-05265-1","article-title":"De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis","volume":"176","author":"Awan","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.bone.2021.115907_bb0510","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s12325-016-0360-3","article-title":"Role of side effects, physician involvement, and patient perception in non-adherence with oral bisphosphonates","volume":"33","author":"Goldshtein","year":"2016","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.bone.2021.115907_bb0515","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2021.115907_bb0520","doi-asserted-by":"crossref","unstructured":"S.L. Ruggiero, T.B. Dodson, J. Fantasia, R. Goodday, T. Aghaloo, B. Mehrotra, F. O'Ryan, O. American Association of, S. Maxillofacial, American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update, J Oral Maxillofac Surg 72(10) (2014) 1938\u201356.","DOI":"10.1016\/j.joms.2014.04.031"},{"issue":"1","key":"10.1016\/j.bone.2021.115907_bb0525","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nrendo.2010.195","article-title":"Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review","volume":"7","author":"Migliorati","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.bone.2021.115907_bb0530","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"issue":"35","key":"10.1016\/j.bone.2021.115907_bb0535","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bone.2021.115907_bb0540","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"9768","key":"10.1016\/j.bone.2021.115907_bb0545","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.115907_bb0550","doi-asserted-by":"crossref","first-page":"115492","DOI":"10.1016\/j.bone.2020.115492","article-title":"Targeting anti-cancer agents to bone using bisphosphonates","volume":"138","author":"Xing","year":"2020","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2021.115907_bb0555","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1021\/bc500614b","article-title":"Novel pullulan bioconjugate for selective breast cancer bone metastases treatment","volume":"26","author":"Bonzi","year":"2015","journal-title":"Bioconjug. Chem."},{"issue":"6","key":"10.1016\/j.bone.2021.115907_bb0560","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.nucmedbio.2006.06.004","article-title":"A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer","volume":"33","author":"El-Mabhouh","year":"2006","journal-title":"Nucl. Med. Biol."},{"issue":"1","key":"10.1016\/j.bone.2021.115907_bb0565","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bone.2010.03.006","article-title":"A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites","volume":"47","author":"Reinholz","year":"2010","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2021.115907_bb0570","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.2018-0707","article-title":"First-in-human phase I study of MBC-11, a novel bone-targeted cytarabine-etidronate conjugate in patients with cancer-induced bone disease","volume":"24","author":"Zinnen","year":"2019","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.bone.2021.115907_bb0575","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1002\/anie.200805133","article-title":"Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate","volume":"48","author":"Miller","year":"2009","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"7","key":"10.1016\/j.bone.2021.115907_bb0580","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/156800910793605767","article-title":"Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases","volume":"10","author":"Salerno","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.bone.2021.115907_bb0585","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/jfb3010079","article-title":"Synthesis and biological evaluation of a new polymeric conjugate and nanocarrier with osteotropic properties","volume":"3","author":"Pignatello","year":"2012","journal-title":"J Funct Biomater"},{"key":"10.1016\/j.bone.2021.115907_bb0590","doi-asserted-by":"crossref","unstructured":"M. Ora, T. Lonnberg, D. Florea-Wang, S. Zinnen, A. Karpeisky, H. Lonnberg, Bisphosphonate derivatives of nucleoside antimetabolites: hydrolytic stability and hydroxyapatite adsorption of 5\u2032-beta,gamma-methylene and 5\u2032-beta,gamma-(1-hydroxyethylidene) triphosphates of 5-fluorouridine and ara-cytidine, J. Organomet. Chem. 73(11) (2008) 4123\u201330.","DOI":"10.1021\/jo800317e"},{"key":"10.1016\/j.bone.2021.115907_bb0595","doi-asserted-by":"crossref","unstructured":"R. Coleman, P. Hadji, J.J. Body, D. Santini, E. Chow, E. Terpos, S. Oudard, O. Bruland, P. Flamen, A. Kurth, C. Van Poznak, M. Aapro, K. Jordan, E.G.C.E.a. clinicalguidelines@esmo.org, Bone health in cancer: ESMO clinical practice guidelines, Ann Oncol 31(12) (2020) 1650-1663.","DOI":"10.1016\/j.annonc.2020.07.019"},{"key":"10.1016\/j.bone.2021.115907_bb0600","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.115907_bb0605","unstructured":"A. Guidelines."},{"key":"10.1016\/j.bone.2021.115907_bb0610","doi-asserted-by":"crossref","unstructured":"A.D. Anastasilakis, S.E. Papapoulos, S.A. Polyzos, N.M. Appelman-Dijkstra, P. Makras, Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial, J Bone Miner Res 34(12) (2019) 2220\u20132228.","DOI":"10.1002\/jbmr.3853"},{"issue":"Suppl. 4","key":"10.1016\/j.bone.2021.115907_bb0615","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.bone.2021.115907_bb0620","unstructured":"Radiology Key.com. https:\/\/radiologykey.com\/bisphosphonates-for-bone-pain-palliation\/#:~:text=Tumour%20Mean%20frequency%20(%)%20Range%20(%)%20Breast%2073,resulting%20in%20considerable%20reduction%20in%20quality%20of%20life."},{"issue":"6","key":"10.1016\/j.bone.2021.115907_bb0625","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.bone.2021.115907_bb0630","first-page":"5437","article-title":"Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor-treated patients with non-small cell lung cancer exhibiting bone metastasis","volume":"18","author":"Cui","year":"2019","journal-title":"Oncol Lett"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:54:23Z","timestamp":1757613263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221000697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":126,"alternative-id":["S8756328221000697"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.115907","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cThe use of bisphosphonates to treat skeletal complications in solid tumours\u201d","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.115907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115907"}}